PA8561101A1 - Benzotiazoles - Google Patents

Benzotiazoles

Info

Publication number
PA8561101A1
PA8561101A1 PA20028561101A PA8561101A PA8561101A1 PA 8561101 A1 PA8561101 A1 PA 8561101A1 PA 20028561101 A PA20028561101 A PA 20028561101A PA 8561101 A PA8561101 A PA 8561101A PA 8561101 A1 PA8561101 A1 PA 8561101A1
Authority
PA
Panama
Prior art keywords
ilo
low molecular
molecular weight
rent
eventually replaced
Prior art date
Application number
PA20028561101A
Other languages
English (en)
Inventor
Alexander Flohr
Claus Riemer
Roland Jakob-Roetne
Roger David Norcross
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PA8561101A1 publication Critical patent/PA8561101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A COMPUESTOS DE LA FORMULA GENERAL 1 EN LA QUE R1 ES EL 3,6-DIHIDRO-2H-PIRAN-4-ILO, EL 5,6-DIHIDRO-4H-PIRAN-3-ILO, EL 5,6-DIHIDRO-4H-PIRAN-2-ILO, EL TETRAHIDROPIRAN-2-,-3- O -4-ILO, EL CICLOHEX-1-ENILO, EL CICLOHEXILO O ES EL 1,2,3,6-TETRAHIDROPIRIDIN-4-ILO O PIPERIDIN-4-ILO, QUE ESTAN EVENTUALMENTE SUSTITUIDOS POR -C(O)CH3 O -C(O)OCH3 EN LA POSICION 1 DEL ATOMO DE N; R2 ES ALQUILO DE BAJO PESO MOLECULAR, PIPERIDIN-1-ILO EVENTUALMENTE SUSTITUIDO POR HIDROXI, O ES FENILO EVENTUALMENTE SUSTITUIDO POR -(CH2)N-N(R´)-C(O)-(CH2)N-NR2´,-(CH2)N-HALOGENO, ALQUILO DE BAJO PESO MOLECULAR O -(CH2)N-N(R´)-(CH2)N-O ALQUILO DE BAJO PESO MOLECULAR; O ES MORFOLINILO O ES PIRIDINILO QUE ESTA EVENTUALMENTE SUSTITUIDO PO HALOGENO, -N(N(R´)-(CH2)N-O-ALQUILO DE BAJO PESO MOLECULAR, ALQUILO DE BAJO PESO MOLECULAR, ALCOXI DE BAJO PESO MOLECULAR, MORFOLINILO O -(CH2)N-PIRROLIDINILO; N ES EL NUMERO 0, 1 O 2; R´ES HIDROGENO O ALQUILO DE BAJO PESO MOLECULAR; Y A SALES DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS. SE HA CONSTATADO QUE LOS COMPUESTOS DE LA FORMULA GENERAL 1 SON LIGANDOS DE RECEPTOR DE ADENOSINA. DE MODO ESPECIFICO, LOS COMPUESTOS DE LA PRESENTE INVENCION TIENEN BUENA AFINIDAD CON EL RECEPTOR A2A Y PUEDEN UTILIZARSE PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON ESTE RECEPTOR.
PA20028561101A 2001-12-12 2002-12-10 Benzotiazoles PA8561101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01129273 2001-12-12

Publications (1)

Publication Number Publication Date
PA8561101A1 true PA8561101A1 (es) 2003-07-28

Family

ID=8179487

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20028561101A PA8561101A1 (es) 2001-12-12 2002-12-10 Benzotiazoles

Country Status (21)

Country Link
US (1) US6734179B2 (es)
EP (1) EP1456202B1 (es)
JP (1) JP4283116B2 (es)
KR (1) KR100582696B1 (es)
CN (1) CN1286834C (es)
AR (1) AR037792A1 (es)
AT (1) ATE309242T1 (es)
AU (1) AU2002356628B2 (es)
BR (1) BR0214837A (es)
CA (1) CA2469876C (es)
DE (1) DE60207294T2 (es)
ES (1) ES2251628T3 (es)
GT (1) GT200200270A (es)
MX (1) MXPA04005554A (es)
PA (1) PA8561101A1 (es)
PE (1) PE20030751A1 (es)
PL (1) PL371064A1 (es)
RU (1) RU2293736C2 (es)
TW (1) TW200409772A (es)
UY (1) UY27578A1 (es)
WO (1) WO2003053961A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100406446C (zh) * 2003-01-13 2008-07-30 弗·哈夫曼-拉罗切有限公司 苯并唑衍生物及其作为腺苷受体配体的用途
US6872833B2 (en) 2003-04-14 2005-03-29 Hoffmann-La Roche Inc. Adenosine receptor ligands
WO2005000842A1 (en) * 2003-05-19 2005-01-06 F. Hoffman-La Roche Ag Benzothiazole derivatives as adenosine receptor ligands
CN1791405A (zh) * 2003-05-21 2006-06-21 弗·哈夫曼-拉罗切有限公司 苯并噻唑衍生物及其在治疗涉及腺苷a 2a受体的疾病中的应用
WO2005028484A1 (en) * 2003-09-19 2005-03-31 F. Hoffmann-La Roche Ag Thiazolopyridine derivatives as adenosine receptor ligands
TWI370820B (en) 2005-04-27 2012-08-21 Takeda Pharmaceutical Fused heterocyclic compounds
WO2008052930A2 (en) * 2006-11-03 2008-05-08 F. Hoffmann-La Roche Ag Preparation of 4-alk0xy-7- (tetrahydropyran-4-yl) benzothiazol-2-amine derivatives
DE102011005232A1 (de) 2011-03-08 2012-09-13 AristoCon GmbH & Co. KG Adenosin und seine Derivate zur Verwendung in der Schmerztherapie
AR117844A1 (es) * 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0113219B1 (en) 1982-12-21 1987-11-19 Johnsen & Jorgensen (Plastics) Limited Dispensing container
EP1037632B1 (en) 1997-11-10 2006-01-11 Bristol-Myers Squibb Company Benzothiazole protein tyrosine kinase inhibitors
CN1328560A (zh) 1998-09-22 2001-12-26 协和发酵工业株式会社 [1,2,4]三唑并[1,5－c]嘧啶衍生物
ATE385794T1 (de) 2000-06-21 2008-03-15 Hoffmann La Roche Benzothiazolderivate zur behandlung von alzheimer und parkinson
US6620811B2 (en) * 2001-11-19 2003-09-16 Hoffmann-La Roche Inc. Isonicotin- and nicotinamide derivatives of benzothiazoles
US6713499B2 (en) * 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives

Also Published As

Publication number Publication date
DE60207294D1 (en) 2005-12-15
UY27578A1 (es) 2003-06-30
US20030144288A1 (en) 2003-07-31
PL371064A1 (en) 2005-06-13
JP4283116B2 (ja) 2009-06-24
DE60207294T2 (de) 2006-07-20
EP1456202B1 (en) 2005-11-09
MXPA04005554A (es) 2004-09-10
KR100582696B1 (ko) 2006-05-23
EP1456202A1 (en) 2004-09-15
CN1602310A (zh) 2005-03-30
RU2004121683A (ru) 2006-01-10
JP2005521647A (ja) 2005-07-21
TW200409772A (en) 2004-06-16
CA2469876A1 (en) 2003-07-03
WO2003053961A1 (en) 2003-07-03
CA2469876C (en) 2011-01-11
RU2293736C2 (ru) 2007-02-20
KR20040073473A (ko) 2004-08-19
AU2002356628A1 (en) 2003-07-09
CN1286834C (zh) 2006-11-29
AU2002356628B2 (en) 2008-04-17
AR037792A1 (es) 2004-12-01
GT200200270A (es) 2003-07-30
BR0214837A (pt) 2004-08-31
ATE309242T1 (de) 2005-11-15
PE20030751A1 (es) 2003-09-05
ES2251628T3 (es) 2006-05-01
US6734179B2 (en) 2004-05-11

Similar Documents

Publication Publication Date Title
ES2643363T3 (es) Sales de 2-fluoro-N-metil-4-[7-(quinolin-6-il-metil)-imidazo[1,2-b][1,2,4]triazin-2-il]benzamida y procesos relacionados con la preparación de las mismas
PA8561101A1 (es) Benzotiazoles
TW200732329A (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
WO2008041053A3 (en) Inhibitors of vegf receptor and hgf receptor signaling
ES2905399T3 (es) Derivados heterocíclicos de seis miembros y composición farmacéutica que los comprende
PA8558001A1 (es) Derivados de isonicotin y nicotinamida de benzotiazoles
MA30709B1 (fr) Derives de pyrido (2, 3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3.
PA8559901A1 (es) Uso de ureas de benzotiazoles
CN101155807A (zh) 具有tie2（tek）抑制活性的化合物
CY1110951T1 (el) Αζαϊνδολες
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
PE20060285A1 (es) Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
GT200100137A (es) Pro-drogas de derivados de 4-fenil-piridina.
MX2009013335A (es) Derivados de piperidina/piperazina.
CY1115643T1 (el) Διεγερτης νευρογενεσης ή θεραπευτικος παραγων νευροπαθειας που περιλαμβανει παραγωγα αλκυλ αιθερα ή αλας αυτου
NO20004485D0 (no) Sykloalkenderivater, deres fremstilling og anvendelse
Long et al. Structure-based drug design: Synthesis and biological evaluation of quinazolin-4-amine derivatives as selective Aurora A kinase inhibitors
BRPI0907122B8 (pt) compostos de piridoindóis (1-azinona) substituídos, composição farmacêutica compreendendo os referidos compostos, e usos dos mesmos
GT200100148A (es) Derivados de 4-fenil-piridina.
NO20076402L (no) Imaging 18F or 11C-labelled alkylthiophenyl guanidines
CN104703985A (zh) 作为pi3-激酶信号通路调节剂的芳基和杂芳基取代的苯衍生物
AR048808A1 (es) Pirrolocarbazoles fusionados
DE60206505D1 (de) Substituierte benzopyran derivate gegen arrhythmie
CN107074873B (zh) 作为抗癌药的7-(吗啉基)-2-(N-哌嗪基)甲基噻吩并[2，3-c]吡啶衍生物
AR045447A1 (es) Compuestos triciclicos inhibidores de transferasa de proteina de farnesilo novedosos como agentes antitumorales